Orexigen Therapeutics Inc., of San Diego, said it received the Day 180 list of outstanding issues (LOI) from the EMA's Committee for Medicinal Products for Human Use (CHMP) for its marketing authorization application for NB32 (naltrexone sustained-release [SR]/bupropion SR), an investigational drug candidate being evaluated for weight loss.